Secondary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy

Sueh-li Lim; John Reynolds; Hang Quach; Anna Hutchinson; Ian H. Kerridge; Jane A. Estell; Craig  Wallington-Gates; Anna Kalff; Flora Yuen; Andrew Spencer

doi:10.1182/blood-2022-170697

Secondary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy

Sueh-li Lim, John Reynolds, Hang Quach, Anna Hutchinson, Ian H. Kerridge, Jane A. Estell, Craig Wallington-Gates, Anna Kalff, Flora Yuen, Andrew Spencer

Australian Centre for Blood Diseases

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	10174-10176
Number of pages	3
Journal	Blood
Volume	140
Issue number	Supplement 1
DOIs	https://doi.org/10.1182/blood-2022-170697
Publication status	Published - 15 Nov 2022
Event	Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) 2022 - New Orleans, United States of America Duration: 10 Dec 2022 → 13 Dec 2022 Conference number: 64th https://www.sciencedirect.com/journal/blood/vol/140/suppl/S1 (Meeting abstract published in Supplementary Issue of Blood) https://www.hematology.org/meetings/annual-meeting

Access to Document

10.1182/blood-2022-170697

Cite this

Lim, S., Reynolds, J., Quach, H., Hutchinson, A., Kerridge, I. H., Estell, J. A., Wallington-Gates, C., Kalff, A., Yuen, F., & Spencer, A. (2022). Secondary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy. Blood, 140(Supplement 1), 10174-10176. https://doi.org/10.1182/blood-2022-170697

@article{0c1941610feb4e02b6d5f2f36d4bd014,

title = "Secondary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy",

author = "Sueh-li Lim and John Reynolds and Hang Quach and Anna Hutchinson and Kerridge, {Ian H.} and Estell, {Jane A.} and Craig Wallington-Gates and Anna Kalff and Flora Yuen and Andrew Spencer",

note = "Poster Abstracts 653.Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials; Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) 2022, ASH 2022 ; Conference date: 10-12-2022 Through 13-12-2022",

year = "2022",

month = nov,

day = "15",

doi = "10.1182/blood-2022-170697",

language = "English",

volume = "140",

pages = "10174--10176",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "Supplement 1",

url = "https://www.sciencedirect.com/journal/blood/vol/140/suppl/S1, https://www.hematology.org/meetings/annual-meeting",

}

Lim, S , Reynolds, J, Quach, H, Hutchinson, A, Kerridge, IH, Estell, JA, Wallington-Gates, C, Kalff, A, Yuen, F & Spencer, A 2022, 'Secondary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy', Blood, vol. 140, no. Supplement 1, pp. 10174-10176. https://doi.org/10.1182/blood-2022-170697

Secondary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy. / Lim, Sueh-li ; Reynolds, John; Quach, Hang et al.
In: Blood, Vol. 140, No. Supplement 1, 15.11.2022, p. 10174-10176.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Secondary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy

AU - Lim, Sueh-li

AU - Reynolds, John

AU - Quach, Hang

AU - Hutchinson, Anna

AU - Kerridge, Ian H.

AU - Estell, Jane A.

AU - Wallington-Gates, Craig

AU - Kalff, Anna

AU - Yuen, Flora

AU - Spencer, Andrew

N1 - Conference code: 64th

PY - 2022/11/15

Y1 - 2022/11/15

UR - https://www.sciencedirect.com/science/article/pii/S0006497122061298

U2 - 10.1182/blood-2022-170697

DO - 10.1182/blood-2022-170697

M3 - Meeting Abstract

SN - 0006-4971

VL - 140

SP - 10174

EP - 10176

JO - Blood

JF - Blood

IS - Supplement 1

T2 - Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) 2022

Y2 - 10 December 2022 through 13 December 2022

ER -

Lim S , Reynolds J, Quach H, Hutchinson A, Kerridge IH, Estell JA et al. Secondary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy. Blood. 2022 Nov 15;140(Supplement 1):10174-10176. doi: 10.1182/blood-2022-170697

Secondary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy

Access to Document

Other files and links

Cite this